Case report: Conversion therapy for advanced intrahepatic cholangiocarcinoma using PD-1 inhibitor plus S-1 and nab-paclitaxel

Intrahepatic cholangiocarcinoma (iCCA) is a highly malignant hepatobiliary tumor with a high rate of advanced disease at initial presentation. Conversion into resectable iCCA is important for improving the prognosis. Immunotherapy-based regimens are being increasingly used for treating advanced iCCA...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xiaocheng, Jiang, Zhiyang, Wu, Yongjuan, Gong, Wei, Liao, Xiaofeng, Li, Xiaogang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9366243/
https://www.ncbi.nlm.nih.gov/pubmed/35965578
http://dx.doi.org/10.3389/fonc.2022.935817
_version_ 1784765518976122880
author Li, Xiaocheng
Jiang, Zhiyang
Wu, Yongjuan
Gong, Wei
Liao, Xiaofeng
Li, Xiaogang
author_facet Li, Xiaocheng
Jiang, Zhiyang
Wu, Yongjuan
Gong, Wei
Liao, Xiaofeng
Li, Xiaogang
author_sort Li, Xiaocheng
collection PubMed
description Intrahepatic cholangiocarcinoma (iCCA) is a highly malignant hepatobiliary tumor with a high rate of advanced disease at initial presentation. Conversion into resectable iCCA is important for improving the prognosis. Immunotherapy-based regimens are being increasingly used for treating advanced iCCA in recent years. However, the use of combined chemotherapy and immunotherapy for conversion has rarely been reported. The aim of this report was to present the outcomes of a 52-year-old female patient with IIIB iCCA. The patient was treated with a programmed cell death protein-1 inhibitor plus S-1 and nab-paclitaxel. The postoperative histopathological results indicated pathologic complete response after six cycles of systematic treatment. The patient is currently disease-free for one year.
format Online
Article
Text
id pubmed-9366243
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93662432022-08-12 Case report: Conversion therapy for advanced intrahepatic cholangiocarcinoma using PD-1 inhibitor plus S-1 and nab-paclitaxel Li, Xiaocheng Jiang, Zhiyang Wu, Yongjuan Gong, Wei Liao, Xiaofeng Li, Xiaogang Front Oncol Oncology Intrahepatic cholangiocarcinoma (iCCA) is a highly malignant hepatobiliary tumor with a high rate of advanced disease at initial presentation. Conversion into resectable iCCA is important for improving the prognosis. Immunotherapy-based regimens are being increasingly used for treating advanced iCCA in recent years. However, the use of combined chemotherapy and immunotherapy for conversion has rarely been reported. The aim of this report was to present the outcomes of a 52-year-old female patient with IIIB iCCA. The patient was treated with a programmed cell death protein-1 inhibitor plus S-1 and nab-paclitaxel. The postoperative histopathological results indicated pathologic complete response after six cycles of systematic treatment. The patient is currently disease-free for one year. Frontiers Media S.A. 2022-07-28 /pmc/articles/PMC9366243/ /pubmed/35965578 http://dx.doi.org/10.3389/fonc.2022.935817 Text en Copyright © 2022 Li, Jiang, Wu, Gong, Liao and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Li, Xiaocheng
Jiang, Zhiyang
Wu, Yongjuan
Gong, Wei
Liao, Xiaofeng
Li, Xiaogang
Case report: Conversion therapy for advanced intrahepatic cholangiocarcinoma using PD-1 inhibitor plus S-1 and nab-paclitaxel
title Case report: Conversion therapy for advanced intrahepatic cholangiocarcinoma using PD-1 inhibitor plus S-1 and nab-paclitaxel
title_full Case report: Conversion therapy for advanced intrahepatic cholangiocarcinoma using PD-1 inhibitor plus S-1 and nab-paclitaxel
title_fullStr Case report: Conversion therapy for advanced intrahepatic cholangiocarcinoma using PD-1 inhibitor plus S-1 and nab-paclitaxel
title_full_unstemmed Case report: Conversion therapy for advanced intrahepatic cholangiocarcinoma using PD-1 inhibitor plus S-1 and nab-paclitaxel
title_short Case report: Conversion therapy for advanced intrahepatic cholangiocarcinoma using PD-1 inhibitor plus S-1 and nab-paclitaxel
title_sort case report: conversion therapy for advanced intrahepatic cholangiocarcinoma using pd-1 inhibitor plus s-1 and nab-paclitaxel
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9366243/
https://www.ncbi.nlm.nih.gov/pubmed/35965578
http://dx.doi.org/10.3389/fonc.2022.935817
work_keys_str_mv AT lixiaocheng casereportconversiontherapyforadvancedintrahepaticcholangiocarcinomausingpd1inhibitorpluss1andnabpaclitaxel
AT jiangzhiyang casereportconversiontherapyforadvancedintrahepaticcholangiocarcinomausingpd1inhibitorpluss1andnabpaclitaxel
AT wuyongjuan casereportconversiontherapyforadvancedintrahepaticcholangiocarcinomausingpd1inhibitorpluss1andnabpaclitaxel
AT gongwei casereportconversiontherapyforadvancedintrahepaticcholangiocarcinomausingpd1inhibitorpluss1andnabpaclitaxel
AT liaoxiaofeng casereportconversiontherapyforadvancedintrahepaticcholangiocarcinomausingpd1inhibitorpluss1andnabpaclitaxel
AT lixiaogang casereportconversiontherapyforadvancedintrahepaticcholangiocarcinomausingpd1inhibitorpluss1andnabpaclitaxel

Ejemplares similares